Patent ID: 11896682
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  C

Claim 6:
7. The conjugate of claim 1, wherein the antibody or antigen-binding fragment thereof has one or more properties selected from the group consisting of:
(i) comprises a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, and 130;
(ii) comprises a LCVR having an amino acid sequence of SEQ ID NO: 138;
(iii) comprises a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128 and 136; and a LCDR3 domain having an amino acid sequence of SEQ ID NO: 144;
(iv) comprises a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 108, 116, 124, and 132; a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, 94, 102, 110, 118, 126, and 134; a LCDR1 domain having an amino acid sequence of SEQ ID NO: 140; and a LCDR2 domain having an amino acid sequence of SEQ ID NO: 142;
(v) is a multi-specific antigen-binding molecule comprising a first binding specificity to MET and a second binding specificity to a tumor specific antigen;
(vi) is a multi-specific antigen-binding molecule comprising a first binding specificity to one epitope of MET and a second binding specificity to a second epitope of MET;
(vii) binds to monomeric human MET with a KD of less than about 230 nM as measured by surface plasmon resonance at 25° C. or 37° C.;
(viii) binds to dimeric human MET with a KD of less than about 3 nM as measured by surface plasmon resonance at 25° C. or 37° C.;
(ix) blocks the binding of HGF to MET; and
(x) suppresses tumor growth and increases survival in subjects with cancer.